Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers: A Systematic Review.
作者信息
Richters Anke, Yildirim Hilin, Booth Christopher M, Vera Badillo Francisco E, Kiemeney Lambertus A L M, Aben Katja K H
机构信息
Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada.
出版信息
JAMA Oncol. 2023 Aug 1;9(8):1144-1147. doi: 10.1001/jamaoncol.2023.1374.
Abstract
摘要
相似文献
1
Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers: A Systematic Review.
JAMA Oncol. 2023 Aug 1;9(8):1144-1147. doi: 10.1001/jamaoncol.2023.1374.
2
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
Int J Urol. 2024 Jan;31(1):25-31. doi: 10.1111/iju.15319. Epub 2023 Oct 15.
3
Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis.
Medicine (Baltimore). 2021 Mar 12;100(10):e19713. doi: 10.1097/MD.0000000000019713.
4
Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review.
Cancer Med. 2021 Aug;10(15):5031-5040. doi: 10.1002/cam4.4086. Epub 2021 Jun 29.
5
Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC.
Br J Cancer. 2020 Aug;123(3):337-338. doi: 10.1038/s41416-020-0918-3. Epub 2020 Jun 16.
6
Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review.
JAMA Netw Open. 2021 Dec 1;4(12):e2139573. doi: 10.1001/jamanetworkopen.2021.39573.
7
Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
Jpn J Clin Oncol. 2021 Jan 1;51(1):28-36. doi: 10.1093/jjco/hyaa187.
8
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis.
Immunotherapy. 2021 May;13(7):621-631. doi: 10.2217/imt-2020-0224. Epub 2021 Mar 29.
9
Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
Future Oncol. 2022 Jan;18(3):403-412. doi: 10.2217/fon-2021-0795. Epub 2021 Nov 17.
10
Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials.
Eur J Clin Pharmacol. 2021 Aug;77(8):1079-1088. doi: 10.1007/s00228-020-03083-9. Epub 2021 Feb 10.
引用本文的文献
1
Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review.
BMC Cancer. 2025 Feb 18;25(1):293. doi: 10.1186/s12885-025-13712-0.
本文引用的文献
1
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers.
JAMA Oncol. 2021 Dec 1;7(12):1843-1850. doi: 10.1001/jamaoncol.2021.4971.
2
JAMA Oncology Patient Page. Immune Checkpoint Inhibitors.
JAMA Oncol. 2015 Apr;1(1):115. doi: 10.1001/jamaoncol.2015.0137.
3
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials.
Open Med. 2010;4(1):e60-8. Epub 2010 Mar 24.
4
Comparison of registered and published primary outcomes in randomized controlled trials.
JAMA. 2009 Sep 2;302(9):977-84. doi: 10.1001/jama.2009.1242.
5
Clinical trial registration: a statement from the International Committee of Medical Journal Editors.
Arch Dermatol. 2005 Jan;141(1):76-7. doi: 10.1001/archderm.141.1.76.
Zotero 插件